Compare how FDA, EU CE, MDSAP, and China NMPA evidence can support multi-country medical device registration, reduce duplicate work, and shape market-entry sequencing.
Reference approvals can improve dossier credibility, support abridged or verification pathways, and reduce evidence-building work. They rarely remove local registration, local holder, labeling, fee, or post-market duties.
How 510(k), De Novo, and PMA outcomes can support global medical device filings without replacing local registration.
Strong dossier credibility in Canada, parts of LATAM, the Middle East, ASEAN, Australia, Japan, and other mature-regulator-aware markets.
How CE technical documentation, clinical evaluation, GSPR, PMS, and notified-body review can support non-EU filings.
Often the most reusable technical-file package for markets using GHTF, IMDRF, CSDT, or EU-aligned evidence structures.
How a Medical Device Single Audit Program audit can reduce quality-system audit duplication across participating and accepting markets.
Can be a prerequisite, substitute, or strong audit-reliance tool depending on the target country.
Where an existing China NMPA registration can create formal, partial, supportive, or dossier-reuse value in overseas filings.
Can help in emerging-market review, distributor due diligence, public procurement, and product-history narratives when the product lacks FDA or CE approval.
